Amicus Therapeutics (FOLD) CAO exits stock and options in BioMarin deal
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics Chief Accounting Officer Samantha Prout reported the cash-out of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical. She disposed of 125,951 shares of Common Stock at $14.50 per share, a figure that includes 47,394 shares of Common Stock and 78,557 restricted stock units that vested in full when the merger was consummated.
Several grants of fully vested stock options covering Amicus Common Stock were also cancelled at closing and converted into cash. For each option grant, she became entitled to a cash payment equal to the difference between the $14.50 merger price and the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows she no longer holds Amicus common shares or stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Prout Samantha
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 2,526 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 3,176 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 37,810 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 55,203 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 43,592 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 62,715 | $0.00 | -- |
| Disposition | Common Stock | 125,951 | $14.50 | $1.83M |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 47,394 shares of Common Stock and 78,557 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 125,951 shares
Merger cash price: $14.50 per share
Common stock portion: 47,394 shares
+5 more
8 metrics
Common shares disposed
125,951 shares
Disposed at $14.50 per share in merger consideration
Merger cash price
$14.50 per share
Cash consideration used for shares and option payout calculations
Common stock portion
47,394 shares
Common Stock included in the 125,951 total disposed in the merger
Restricted stock units vested
78,557 units
RSUs that vested in full upon consummation of the BioMarin merger
Option strike price example
$9.41 per share
Exercise price for one cancelled stock option grant converted to cash
Option strike price example
$14.24 per share
Exercise price for another cancelled stock option grant
Post-transaction common holdings
0 shares
Total Amicus common stock held after merger-related dispositions
Post-transaction stock options
0 options
Total derivative securities held after option cancellation for cash
Key Terms
restricted stock units, stock options, disposition to issuer, Merger, +1 more
5 terms
restricted stock units financial
"which included 47,394 shares of Common Stock and 78,557 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
disposition to issuer financial
"transaction_code_description": "Disposition to issuer""
Merger financial
"in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
exercise price financial
"the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What did Amicus Therapeutics (FOLD) executive Samantha Prout report on this Form 4?
She reported disposing of her Amicus equity in connection with the merger with BioMarin. Common shares, restricted stock units, and multiple stock option grants were all cancelled and converted into cash consideration at the merger closing.
What happened to Samantha Prout’s Amicus (FOLD) stock options in the BioMarin merger?
Each reported stock option was cancelled at closing and converted into a right to receive cash. The cash equals $14.50 per share minus the option’s exercise price, multiplied by the number of option shares, with all options described as fully vested in the filing.
Were Samantha Prout’s Amicus (FOLD) restricted stock units affected by the merger?
Yes. The filing states that 78,557 restricted stock units vested in full in connection with consummation of the merger. Those vested units, together with her common shares, were disposed of for cash based on the $14.50 per share merger consideration.
Does Samantha Prout still hold Amicus Therapeutics (FOLD) stock or options after the merger?
According to the reported post-transaction balances, she no longer holds Amicus common stock or stock options. The Form 4 shows zero shares and zero derivative securities remaining after her equity was cancelled and cashed out in the BioMarin acquisition.